Work

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3155

Authors: Jibran Ahmed, Jennifer Zlott, Jared C. Foster, Sarah Shin, Geraldine Helen O'Sullivan Coyne, Naoko Takebe, Ning Ma, S. Percy Ivy, James H. Doroshow, Alice P. Chen

Institutions: National Institutes of Health, National Cancer Institute, Mater Misericordiae University Hospital, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4410823137

Cites:

Cited by:

Related to: 10